What is DARE's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DARE?

P/E (TTM) is n/a and 52-week range is $0.63 to $3.78 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DARE figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DARE?

The company profile lists revenue (TTM) near $2M, net income (TTM) near -$1.45B, EPS (TTM) near -$0.79 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Dare Bioscience Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 19.7M shares outstanding, ISIN US23666P2002 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Dare Bioscience Inc

$DARE

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 21 full-time employees. The company went IPO on 2014-04-10. The firm's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.

Employees

Website

www.darebioscience.com

IPO

2014-04-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US23666P2002

Headquarters

San Diego, California, US

Shares outstanding

19.7M

NAICS sector

Manufacturing

Institutional ownership

13.66%

Browse other companiesFree AI scores and summaries for more stocks